Author: Foundation Venture Capital Group, LLC
Source: Foundation Venture Capital Group, LLC
Interest: GeneAssess, Inc., a New Jersey-based biotechnology company, has received a commitment of up to $500,000 from Foundation Venture Capital Group (FVCG), Inc., to validate FRY, a cancer molecular signature gene discovered by GeneAssess scientists that could provide a more accurate diagnostic biomarker for cancer staging.
Link: http://www.sacbee.com/2012/06/29/4599159/foundation-venture-capital-group.html
Loading...